stockrowViatris Inc.
VTRS Healthcare Drug Manufacturers Specialty & Generic
Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024.
- Revenue
- −0.28%
- EPS
- −154.6%
- Free cash flow
- +38.8%
- Total debt
- −89.4%
Quarter to September 2026, against a year earlier
Follow VTRS
Alert me
Viatris Inc. (VTRS) Net income
Viatris Inc.'s net income for fiscal 2025 was −$3.5B, compared with −$634.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$607.8M. Over the past ten years it has ranged from −$3.5B (fiscal 2025) to $2.1B (fiscal 2022) — the current reading is the lowest in ten years. Net income has fallen for 3 consecutive fiscal years. Viatris Inc. ranks 83rd of 84 Drug Manufacturers Specialty & Generic companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$3.5B | — |
| FY2024 | −$634.2M | — |
| FY2023 | $54.7M | (97.37%) |
| FY2022 | $2.1B | — |
| FY2021 | −$1.3B | — |
| FY2020 | −$669.9M | — |
| FY2019 | $16.8M | (95.23%) |
| FY2018 | $352.5M | (49.35%) |
| FY2017 | $696.0M | 45.00% |
| FY2016 | $480.0M | (43.38%) |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$325.3M | — |
| Jun 2026 | −$118.8M | — |
| Mar 2026 | $176.4M | — |
| Dec 2025 | −$340.1M | — |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| HLN Haleon PLC Sponsored ADR compare | $3.1B |
| ZTS Zoetis Inc. compare | $2.6B |
| UTHR United Therapeutics Corporation compare | $1.2B |
| NBIX Neurocrine Biosciences, Inc. compare | $702.5M |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $508.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $273.0M |
| ALKS Alkermes plc compare | −$351.0K |
| ELAN Elanco Animal Health Incorporated compare | −$199.0M |
| VTRS Viatris Inc. | −$607.8M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on VTRS
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement